The Symposium, co-sponsored by the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology, will be held Thursday through Saturday, November 17-19 at the National Institutes of Health’s Rockville, Maryland.

The goal of the symposium is to develop evidence-based recommendations for cervical cancer screening that consider if, and if so, how molecular testing should be incorporated into screening strategies. Six Work Groups, focused on specific Key Questions1, are reviewing the evidence and will develop draft documents prior to the meeting. The AHRQ evidence reports2,3 that were developed in preparation for the USPSTF meeting on cervix held in March of this year will form the basis for our evidence assessment; gaps in the data will be addressed by the individual Work Groups. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system4 for guidelines development will be used. Directly following this meeting, the American Cancer Society (ACS) will convene an ACS-appointed panel to vote on revisions to the ACS cervical cancer screening guidelines.

  1. ASCCP Practice Management: PISCM, Molecular Symposium web page; link)
  2. Agency for Healthcare Research and Quality; link)
  3. Agency for Healthcare Resaerch and Quality; link)
  4. GRADE Website; link)

From October 10 through October 25, the draft recommendations from each of the six Work Groups will be posted on a public bulletin board hosted on the ASCCP website, and we would ask you and your organization’s leadership to review this board and provide us with your feedback.

Posted with permission of American Society of Cytopathology, Elizabeth Jenkins,